Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413988 | 0.86 | DYRK1A (0.61) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15472022 | 0.84 | LMNA (0.64) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29819802 | 0.80 | KMT2A (0.56) | MEN1KMT2AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL1221564 | 0.80 | MEN1 (0.61) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL31130219 | 0.79 | MAPT (0.60) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29819664 | 0.79 | MAPT (0.60) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20600262 | 0.79 | L3MBTL1 (0.54) | MEN1KMT2AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL12922084 | 0.79 | KMT2A (0.54) | MEN1KMT2AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL11021202 | 0.78 | SLC6A4 (0.55) | MEN1KMT2AALDH1A1SLC6A4MAPT | |
| SCHEMBL13426507 | 0.77 | LMNA (0.69) | LMNAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| EP-3942934-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11155522-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| CN-107635404-B | MCT4 inhibitors for the treatment of disease | 威特瑞有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210009524-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2021-01-14 | — | — | US | disclosed |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-10202350-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3307068-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-15 | — | — | US | disclosed |
| WO-2016201426-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-11155522-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-10202350-B2 | MCT4 inhibitors for treating disease | SLC16A3, SLC16A1, MCTS1 | LMNA 3600/4885MEN1 1340/4885KMT2A 3004/4885 |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | LMNA 3182/4885MEN1 287/4885KMT2A 2226/4885 |
| US-20210009524-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A3, SLC16A1, MCTS1 | LMNA 3600/4885MEN1 1340/4885KMT2A 3004/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | LMNA 2639/4885MEN1 339/4885KMT2A 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.